- $55.15m
- $64.20m
- $0.20m
Clene Inc. reports results for the quarter ended December 31 - Earnings Summary
Clene Inc. expected to post a loss of 95 cents a share - Earnings Preview
Advisory: Alert incorrectly tagged to Canadian National Railway withdrawn
Clene Inc. expected to post a loss of 95 cents a share - Earnings Preview
Brief: Clene Files For Offering Of Up To 2.4 Million Shares Of Common Stock By Selling Securityholders- SEC Filing
Clene Inc. reports results for the quarter ended September 30 - Earnings Summary
Clene Inc. expected to post a loss of $1.32 a share - Earnings Preview
Brief: Clene Announces Closing Of $7.3 Million Registered Direct Offering And Concurrent Private Placements And Amendment Of Debt Facility
Brief: Clene Inc. - Co, Unit Enters Third Amendment To Loan And Security Agreement
Brief: Clene Announces $7.3 Mln Registered Direct Offering, Concurrent Private Placements Priced At Market Under Nasdaq Rules
Clene Inc. expected to post a loss of $1.43 a share - Earnings Preview
Brief: Clene Regains Compliance With Nasdaq Listing Rule 5550(A)(2) For Continued Listing On Nasdaq
Brief: Clene Announces 1-For-20 Reverse Stock Split
Brief: Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting
Brief: Clene Provides Update On Its Nih-Funded Expanded Access Program For Cnm-Au8® In Als (Act-Eap)
Clene Inc. reports results for the quarter ended in March - Earnings Summary
Clene Inc. expected to post a loss of 8 cents a share - Earnings Preview
Brief: Clene Says On April 25, Co, Unit Got Into Amended & Restated Exclusive Supply Agreement,Amended & Restated License Agreement With 4Life Research
Clene Inc. reports results for the quarter ended in December - Earnings Summary